SCHEMBL3288014

SCHEMBL3288014

CC(C)c1ccc(Oc2ccc3c4c(cccc24)C(=O)N(c2ccccc2)C3=O)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 6/20 0.53
▸ BCL2 P10415 5/20 0.53
▸ BCL2L1 Q07817 4/20 0.53
▸ KMT2A Q03164 8/20 0.51
▸ KDM4E B2RXH2 5/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ USP2 O75604 4/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ MAPT P10636 3/20 0.51
▸ HTT P42858 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ KEAP1 Q14145 2/20 0.51
▸ NFE2L2 Q16236 2/20 0.51
▸ POLB P06746 2/20 0.49
▸ APOBEC3A P31941 1/20 0.49
▸ RECQL P46063 1/20 0.49
▸ CASP6 P55212 1/20 0.49
▸ APOBEC3G Q9HC16 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3284746 0.85 MCL1 (0.52) MCL1BCL2BCL2L1KMT2AKDM4E
SCHEMBL28533652 0.84 KMT2A (0.51) MCL1BCL2KMT2AKDM4EALDH1A1
SCHEMBL14935514 0.82 MCL1 (0.60) MCL1BCL2BCL2L1KMT2AKDM4E
SCHEMBL3285110 0.80 MCL1 (0.56) MCL1BCL2KMT2AKDM4EALDH1A1
SCHEMBL14003750 0.79 ANPEP (0.42) MCL1BCL2BCL2L1KMT2AKDM4E
SCHEMBL17948241 0.79 PRMT1 (0.68) KMT2AKDM4EALDH1A1USP2MEN1
SCHEMBL14003757 0.77 ANPEP (0.56) MCL1BCL2BCL2L1KMT2AKDM4E
SCHEMBL11210959 0.76 KMT2A (0.44) MCL1BCL2KMT2AKDM4EALDH1A1
SCHEMBL3284775 0.76 MCL1 (0.46) MCL1BCL2BCL2L1KMT2AKDM4E
SCHEMBL14003739 0.76 ANPEP (0.45) MCL1BCL2BCL2L1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7714044-B2 Use of 4-cyano-naphthalene-1, 8-dicarboximide derivatives and related compounds to protect organic material from the damaging effects of light BASF AKITENGESELLSCHAFT (DE) 2010-05-11 — — US disclosed
US-20070100033-A1 Use of 4-cyano-naphthalene-1, 8-dicarboximide derivatives and related compounds to protect organic material from the damaging effects of light BAST AKTIENGESELLSCHAFT (DE) 2007-05-03 — — US disclosed
US-20050171252-A1 Use of naphthalin-1,8-dicarboxylic acid monoimides BASF AKTIENGESELLSCHAFT (DE) 2005-08-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171252-A1 Use of naphthalin-1,8-dicarboxylic acid monoimides NDC1, NDUFC1, NDUFC2 MCL1 2655/4885BCL2 1238/4885BCL2L1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback